Written by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories
As we start a new year, the clinical diagnostics industry finds itself at the intersection of rapid technological progress and significant uncertainty. I anticipate that continued innovation amid this uncertainty will mark 2026. Below are some of the specific opportunities and challenges ahead for laboratory medicine this year.
Wearables and at-home testing empower patient-driven diagnostics
In 2026, patient-driven diagnostics will continue to gain momentum. The miniaturization of diagnostic technologies is accelerating this trend, with glucose monitors and health trackers now widely adopted. As devices become smaller and more sophisticated, they deliver real-time insights and are expanding beyond wearables to enable more at-home diagnostic solutions. Looking ahead, economic pressures and technological innovation will further push diagnostics into the home, making testing more accessible and personalized.
This surge in patient-led testing brings new challenges for healthcare, which must balance the benefits of patient empowerment with the need for quality and reliability. Concerns around data privacy, test accuracy, and potential misuse underscore the need for updated ethical guidelines and oversight to maintain trust and integrity in lab testing. Additionally, physicians face growing complexity in interpreting results and ensuring appropriate follow-up care when they are no longer initiating tests by ordering them during traditional patient encounters.
AI advances at breakneck speed drive breakthroughs in diagnostics
Artificial intelligence (AI) will remain a major focus of interest and investment. With progress accelerating at an extraordinary pace, AI capabilities by the end of 2026 will far surpass what’s possible today. As this evolution unfolds, the industry must transition from exploring conceptual possibilities to implementing targeted, practical applications that directly enhance patient care and advance research.
One promising area is the integration of AI-driven modeling with structural biology, a discipline that examines the three-dimensional structures of biological macromolecules such as proteins, nucleic acids, and lipids to understand their function. Once primarily the domain of pharmaceutical research, recent advances have made structural biology technology more accessible, positioning it to enter mainstream diagnostics. It has the potential to enable more accurate predictions of patient responses to therapies and support the development of next-generation diagnostic tools that transform how clinicians detect and manage diseases.
Increased connectedness creates both opportunity and risk
A common thread across these trends is the growing sense of connectedness. Data from patient wearables is increasingly integrated with clinical testing, while healthcare information consolidates across fewer platforms. This convergence creates opportunities for true multi-omics diagnostics that combine genomics, proteomics, metabolomics, and other data to deliver comprehensive and personalized diagnostic insights.
Yet this connectedness introduces vulnerabilities. It concentrates data and AI capabilities within a handful of technology providers, raising sustainability and security concerns. Data center outages in 2025 underscored how a single point of failure can disrupt critical tools on a global scale when many organizations rely on the same service provider. At the same time, people also remain concerned about data privacy, and governments view data use as a matter of national security, raising additional challenges for using the data.
Multi-cancer detection remains a focus, with hurdles ahead
Multi-cancer detection (MCD) will remain a major focus in 2026. These tests aim to detect signals from multiple cancer types using a single sample. While no FDA-approved tests exist, some MCD tests are available as lab-developed tests. Companies have invested heavily in multi-cancer detection, signaling strong confidence in their potential. However, challenges remain, including reimbursement hurdles and a lack of infrastructure to support follow-up care for patients with positive results. Still, interest in bringing these tests to market remains high because they offer long-term potential to expand access, catch cancer earlier, and improve survival outcomes.
Advancement continues amid uncertainty
Despite the promise of innovative technologies, investment in diagnostic innovation remains cautious beyond AI and multi-cancer detection as the industry navigates an uncertain economic landscape and changing global trends. Rising costs for manufacturers and ongoing reimbursement hurdles in many countries are limiting access to and adoption of diagnostic solutions. Combined with regulatory uncertainty and regional differences in data privacy, this creates a complex environment for advancing some laboratory medicine innovations.
As 2026 unfolds, the clinical diagnostics industry stands at a moment where innovation and uncertainty coexist. And while this combination brings risk, it also holds the potential to truly revolutionize diagnostics in a way that increases accessibility and improves outcomes for patients and populations around the globe. For this potential to be achieved, it is vital that laboratorians and healthcare professionals be engaged, stay informed, remain adaptable, and create strategic collaborations, all while keeping the people we serve at the center.
The editorial staff had no role in this post's creation.